Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease

Parakkal Deepak; William J. Sandborn

doi:10.1016/j.gtc.2017.05.013

Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease

Parakkal Deepak, William J. Sandborn

Research output: Contribution to journal › Review article › peer-review

43 Scopus citations

Abstract

This article reviews the available data regarding the efficacy of ustekinumab across published randomized clinical trials and open-label experience from tertiary medical centers, safety data, including in pregnancy, and its use in patients who have failed tumor necrosis factor (TNF) antagonists as well as patients who have not failed TNF antagonists. We have proposed an algorithm for positioning the use of ustekinumab among other agents (TNF antagonists, vedolizumab) in moderate-severe Crohn's disease. The article also enumerates drugs that are specific interleukin-23 blockers, including brazikumab (MEDI2070), risankizumab, LY3074828, tildrakizumab, and guselkumab, and the current status of their clinical trials.

Original language	English
Pages (from-to)	603-626
Number of pages	24
Journal	Gastroenterology Clinics of North America
Volume	46
Issue number	3
DOIs	https://doi.org/10.1016/j.gtc.2017.05.013
State	Published - Sep 2017

Keywords

Crohn's disease
Inflammatory bowel disease
Interleukin-12
Interleukin-12/23 monoclonal antibody
Interleukin-23
Ustekinumab

Access to Document

10.1016/j.gtc.2017.05.013

Cite this

@article{9dfbdf4b09e2467e9043068d2cf24f11,

title = "Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease",

abstract = "This article reviews the available data regarding the efficacy of ustekinumab across published randomized clinical trials and open-label experience from tertiary medical centers, safety data, including in pregnancy, and its use in patients who have failed tumor necrosis factor (TNF) antagonists as well as patients who have not failed TNF antagonists. We have proposed an algorithm for positioning the use of ustekinumab among other agents (TNF antagonists, vedolizumab) in moderate-severe Crohn's disease. The article also enumerates drugs that are specific interleukin-23 blockers, including brazikumab (MEDI2070), risankizumab, LY3074828, tildrakizumab, and guselkumab, and the current status of their clinical trials.",

keywords = "Crohn's disease, Inflammatory bowel disease, Interleukin-12, Interleukin-12/23 monoclonal antibody, Interleukin-23, Ustekinumab",

author = "Parakkal Deepak and Sandborn, {William J.}",

year = "2017",

month = sep,

doi = "10.1016/j.gtc.2017.05.013",

language = "English",

volume = "46",

pages = "603--626",

journal = "Gastroenterology Clinics of North America",

issn = "0889-8553",

number = "3",

}

TY - JOUR

T1 - Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease

AU - Deepak, Parakkal

AU - Sandborn, William J.

PY - 2017/9

Y1 - 2017/9

N2 - This article reviews the available data regarding the efficacy of ustekinumab across published randomized clinical trials and open-label experience from tertiary medical centers, safety data, including in pregnancy, and its use in patients who have failed tumor necrosis factor (TNF) antagonists as well as patients who have not failed TNF antagonists. We have proposed an algorithm for positioning the use of ustekinumab among other agents (TNF antagonists, vedolizumab) in moderate-severe Crohn's disease. The article also enumerates drugs that are specific interleukin-23 blockers, including brazikumab (MEDI2070), risankizumab, LY3074828, tildrakizumab, and guselkumab, and the current status of their clinical trials.

AB - This article reviews the available data regarding the efficacy of ustekinumab across published randomized clinical trials and open-label experience from tertiary medical centers, safety data, including in pregnancy, and its use in patients who have failed tumor necrosis factor (TNF) antagonists as well as patients who have not failed TNF antagonists. We have proposed an algorithm for positioning the use of ustekinumab among other agents (TNF antagonists, vedolizumab) in moderate-severe Crohn's disease. The article also enumerates drugs that are specific interleukin-23 blockers, including brazikumab (MEDI2070), risankizumab, LY3074828, tildrakizumab, and guselkumab, and the current status of their clinical trials.

KW - Crohn's disease

KW - Inflammatory bowel disease

KW - Interleukin-12

KW - Interleukin-12/23 monoclonal antibody

KW - Interleukin-23

KW - Ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=85028683195&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2017.05.013

DO - 10.1016/j.gtc.2017.05.013

M3 - Review article

C2 - 28838418

AN - SCOPUS:85028683195

SN - 0889-8553

VL - 46

SP - 603

EP - 626

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

IS - 3

ER -

Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this